Topical steroids may induce a rise in intraocular pressure. The risk may increase with prolonged use, high frequency of administration, young age, higher ocular penetrance and higher anti-inflammatory potency. We aimed to study this relationship by comparing published rates of intraocular pressure elevation following administration of topical steroids and compared the risk of higher versus lower dosage regimes, high- versus low-potency/penetration steroids and adults versus children. Data sources used were Ovid Embase, Ovid Medline, the Cochrane Central Register of Controlled Trials, Web of Science, Scopus, CINHAL Plus and LILACS. Eligible studies were randomised controlled trials of topical steroids versus any other topical steroid, nonsteroidal anti-inflammatory drugs, placebo or vehicle, or a different mode of administration administered for 7 days or longer that reported intraocular pressure elevation from baseline as >10, 6–15 or >15 mm Hg in adults or children. Risks of bias were reviewed using the GRADE quality approach. Data were extracted into the software package, RevMan, Version 5 (Cochrane Collaboration). In total, 43 studies were included. Meta-analysis was not possible. Topical steroids of lower anti-inflammatory potency, and with reduced intraocular penetration, are associated with reduced incidence of intraocular pressure elevation. A comparison of data in children and adults is limited by the use of different reporting systems. The principal obstacle to meta-analysis is the different reporting systems used to categorise intraocular pressure elevation. We recommend future studies should report intraocular pressure elevation >10 mm Hg from baseline to allow meta-analysis of data.
RhenTCidlowskiJA.Antiinflammatory action of glucocorticoids – new mechanisms for old drugs. N Engl J Med2005; 353(16): 1711–1723.
2.
ZhangXClarkAFYorioT.FK506-binding protein 51 regulates nuclear transport of the glucocorticoid receptor beta and glucocorticoid responsiveness. Invest Ophthalmol Vis Sci2008; 49(3): 1037–1047.
3.
KaurSDhimanIKaushikS, et al. Outcome of ocular steroid hypertensive response in children. J Glaucoma2016; 25(4): 343–347.
4.
SpaethGLMonteiro de BarrosDSFudembergSJ.Visual loss caused by corticosteroid-induced glaucoma: how to avoid it. Retina2009; 29(8): 1057–1061.
5.
ArmalyMF.Statistical attributes of the steroid hypertensive response in the clinically normal eye I: the demonstration of three levels of response. Invest Ophthalmol1965; 4: 187–197.
6.
BrookesJLKhawPT.Steroid response in children. Clin Exp Ophthalmol2005; 33: 229–230.
7.
OhjiMKinoshitaSOhmiE, et al. Marked intraocular pressure response to instillation of corticosteroids in children. Am J Ophthalmol1991; 112(4): 450–454.
8.
KwokAKLamDSNgJS, et al. Ocular-hypertensive response to topical steroids in children. Ophthalmology1997; 104: 2112–2116.
9.
LamDSFanDSNgJS, et al. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin Exp Ophthalmol2005; 33(3): 252–258.
10.
NgJSFanDSYoungAL, et al. Ocular hypertensive response to topical dexamethasone in children: a dose-dependent phenomenon. Ophthalmology2000; 107(11): 2097–2100.
11.
AwanMAAgarwalPKWatsonDG, et al. Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance. Br J Ophthalmol2009; 93(6): 708–713.
12.
HingoraniMMoodaleyLCalderVL, et al. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology1998; 105(9): 1715–1720.
13.
DruzgalaPWuWMBodorN.Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res1991; 10(10): 933–937.
14.
Lloyd-JonesDTokarewiczAWatsonPG.Clinical evaluation of clobetasone butyrate eye drops in episcleritis. Br J Ophthalmol1981; 65(9): 641–643.
15.
FiniMESchwartzSGGaoX, et al. Steroid-induced ocular hypertension/glaucoma: focus on pharmacogenomics and implications for precision medicine. Prog Retin Eye Res2017; 56: 58–83.
16.
KempenJHTekle-HaimanotRHundumaL, et al. Fluorometholone 0.1% as ancillary therapy for trachomatous trichiasis surgery: randomized clinical trial. Am J Ophthalmol2019; 197: 145–155.
17.
KimTSallKHollandEJ, et al. Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery. Clin Ophthalmol2019; 13: 69–86.
18.
SheppardJDFosterCSToyosMM, et al. Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: pooled efficacy analysis of two phase 3 studies. Ocul Immunol Inflamm2019; 27(3): 484–496.
19.
Al HanainehATHassaneinDHAbdelbakySH, et al. Steroid-induced ocular hypertension in the pediatric age group. Eur J Ophthalmol2018; 28(4): 372–377.
20.
FongRSilversteinBEPeaceJH, et al. Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery. J Cataract Refract Surg2018; 44(10): 1220–1229.
21.
Shokoohi-RadSDaneshvarRJafarian-ShahriM, et al. Comparison between betamethasone, fluorometholone and loteprednol etabonate on intraocular pressure in patients after keratorefractive surgery. J Curr Ophthalmol2018; 30(2): 130–135.
22.
MifflinMDBettsBSFrederickPA, et al. Efficacy and safety of a 3-month loteprednol etabonate 0.5% gel taper for routine prophylaxis after photorefractive keratectomy compared to a 3-month prednisolone acetate 1% and fluorometholone 0.1% taper. Clin Ophthalmol2017; 11: 1113–1118.
23.
ComstockTLDeCoryHH.Loteprednol etabonate 0.5%/tobramycin 0.3% compared with dexamethasone 0.1%/tobramycin 0.3% for the treatment of blepharitis. Ocul Immunol Inflamm2017; 25(2): 267–274.
24.
KarimianFFaramarziAFekriS, et al. Comparison of loteprednol with fluorometholone after myopic photorefractive keratectomy. J Ophthalmic Vis Res2017; 12(1): 11–16.
25.
PriceMOFengMTScanameoA, et al. Loteprednol etabonate 0.5% gel vs. prednisolone acetate 1% solution after descemet membrane endothelial keratoplasty: prospective randomized trial. Cornea2015; 34(8): 853–858.
26.
BoyntonGERaoofDNiziolLM, et al. Prospective randomized trial comparing efficacy of topical loteprednol etabonate 0.5% versus cyclosporine-A 0.05% for treatment of dry eye syndrome following hematopoietic stem cell transplantation. Cornea2015; 34(7): 725–732.
27.
LeeHChungBKimKS, et al. Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial. Am J Ophthalmol2014; 158(6): 1172–1183e1.
28.
RajpalRKFongRComstockTL.Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies. Adv Ther2013; 30(10): 907–923.
29.
LaneSSHollandEJ.Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. J Cataract Refract Surg2013; 39(2): 168–173.
30.
ComstockTLPaternoMRBatemanKM, et al. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatr Drugs2012; 14(2): 119–130.
31.
ChenMGongLSunX, et al. A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. Curr Med Res Opin2012; 28(3): 385–394.
32.
FongRLeitritzMSiou-MermetR, et al. Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial. Clin Ophthalmol2012; 6: 1113–1124.
33.
GongLSunXQuJ, et al. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients. Clin Ther2012; 34(6): 1259–1272.e1.
34.
ComstockTLPaternoMRSinghA, et al. Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery. Clin Ophthalmol2011; 5: 177–186.
35.
DielemanMWubbelsRJvan Kooten-NoordzijM, et al. Single perioperative subconjunctival steroid depot versus postoperative steroid eyedrops to prevent intraocular inflammation and macular edema after cataract surgery. J Cataract Refract Surg2011; 37(9): 1589–1597.
36.
DonnenfeldEDHollandEJSolomonKD, et al. A multicenter randomized controlled fellow eye trial of pulse-dosed difluprednate 0.05% versus prednisolone acetate 1% in cataract surgery. Am J Ophthalmol2011; 152(4): 609–617. e1.
37.
TorkildsenGLCockrumPMeierE, et al. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. Curr Med Res Opin2011; 27(1): 171–178.
38.
FosterCSDavanzoRFlynnTE, et al. Durezol (difluprednate ophthalmic emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Ther2010; 26(5): 475–483.
39.
HollandEJBartlettJDPaternoMR, et al. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea2008; 27(1): 50–55.
40.
WhiteEMMacyJIBatemanKM, et al. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin2008; 24(1): 287–296.
41.
RussoSPapaVDi BellaA, et al. Dexamethasone-netilmicin: a new ophthalmic steroid-antibiotic combination. Efficacy and safety after cataract surgery. Eye (Lond)2007; 21: 58–64.
42.
NotivolRBertinDAminD, et al. Comparison of topical tobramycin-dexamethasone with dexamethasone-neomycin-polymyxin and neomycin-polymyxin-gramicidin for control of inflammation after cataract surgery: results of a multicenter, prospective, three-arm, randomized, double-masked, controlled, parallel-group study. Clin Ther2004; 26(8): 1274–1285.
43.
FanDSYuCBChiuTY, et al. Ocular-hypertensive and anti-inflammatory response to rimexolone therapy in children. Arch Ophthalmol2003; 121(12): 1716–1721.
44.
LaurellCGZetterstromC.Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery. Brit J Ophthalmol2002; 86: 1380–1384.
45.
LeonardiAPapaVMilazzoG, et al. Efficacy and safety of desonide phosphate for the treatment of allergic conjunctivitis. Cornea2002; 21(5): 476–481.
46.
FanDSNgJSLamDS.A prospective study on ocular hypertensive and antiinflammatory response to different dosages of fluorometholone in children. Ophthalmology2001; 108(11): 1973–1977.
47.
PriceFWJrWillesLPriceM, et al. A prospective, randomized comparison of the use versus non-use of topical corticosteroids after laser in situ keratomileusis. Ophthalmology2001; 108(7): 1236–1244: discussion 1244–1245.
48.
Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group. Am J Ophthalmol1999; 127: 537–544.
49.
ShulmanDGLothringerLLRubinJM, et al. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology1999; 106: 362–369.
50.
A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2. Ophthalmology1998; 105: 1780–1786.
51.
DellSJLowryGMNorthcuttJA, et al. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol1998; 102: 251–255.
52.
DellSJShulmanDGLowryGM, et al. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group. Am J Ophthalmol1997; 123(6): 791–797.
53.
FriedlaenderMHHowesJ.A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol1997; 123(4): 455–464.
54.
AsbellPHowesJ.A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J1997; 23: 31–36.
55.
FosterCSAlterGDeBargeLR, et al. Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis. Am J Ophthalmol1996; 122(2): 171–182.
56.
NuyenBWeinrebRNRobbinsSL.Steroid-induced glaucoma in the pediatric population. J AAPOS2017; 21: 1–6.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
